Corline Biomedical AB (SE:CLBIO)
:CLBIO
Top Page
Corline Biomedical AB
(CLBIO)
Select Model
Select Model
Rating:46Neutral
Price Target:
kr16.00
▼(-2.44% Downside)
Action:ReiteratedDate:02/18/26
The score is held down primarily by weakening operating performance and persistent negative free cash flow, with additional pressure from bearish technical momentum. A debt-free balance sheet with stable equity provides a meaningful cushion, preventing a lower score, while valuation is constrained by ongoing losses and no dividend support.
Positive Factors
Debt-free balance sheet
A zero-debt capital structure materially reduces refinancing risk and interest-cost pressure, giving management flexibility to fund operations or strategic initiatives from equity or cash. Over a 2–6 month horizon this lowers bankruptcy risk and preserves optionality for partnerships or M&A.
Negative Factors
Sharp revenue contraction
Significant and sustained top-line deterioration undermines economies of scale and suggests weak commercial traction or customer concentration. Over months this reduces bargaining power with partners, limits ability to absorb fixed costs, and makes margin recovery harder absent clear commercial turnaround.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt capital structure materially reduces refinancing risk and interest-cost pressure, giving management flexibility to fund operations or strategic initiatives from equity or cash. Over a 2–6 month horizon this lowers bankruptcy risk and preserves optionality for partnerships or M&A.
Read all positive factors
Corline Biomedical AB (CLBIO) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr421.34M
Dividend YieldN/A
Average Volume (3M)90.01K
Price to Earnings (P/E)―
Beta (1Y)0.05
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.20
Shares Outstanding25,613,550
10 Day Avg. Volume161,073
30 Day Avg. Volume90,008
Financial Highlights & Ratios
PEG Ratio0.62
Price to Book (P/B)4.33
Price to Sales (P/S)53.02
P/FCF Ratio-22.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.7
Revenue Forecast (FY)kr54.90M
Corline Biomedical AB Business Overview & Revenue Model
Company Description
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a he...
How the Company Makes Money
null...
Corline Biomedical AB Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.65M | 9.78M | 25.03M | 23.55M | 7.06M |
| Gross Profit | -14.21M | 13.44M | 28.38M | 22.73M | 9.10M |
| EBITDA | -14.12M | -23.07M | -1.69M | 2.38M | -6.88M |
| Net Income | -14.71M | -23.19M | -1.81M | 2.33M | -6.92M |
Balance Sheet | |||||
| Total Assets | 98.58M | 94.76M | 100.11M | 101.78M | 101.66M |
| Cash, Cash Equivalents and Short-Term Investments | 20.56M | 17.67M | 17.01M | 26.21M | 41.63M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 4.82M | 7.85M | 6.79M | 7.19M | 9.43M |
| Stockholders Equity | 93.76M | 86.91M | 93.32M | 94.59M | 92.23M |
Cash Flow | |||||
| Free Cash Flow | -17.74M | -16.14M | -9.73M | -15.45M | -14.45M |
| Operating Cash Flow | -17.69M | -8.64M | 886.00K | -6.45M | -4.83M |
| Investing Cash Flow | -982.00K | -7.50M | -10.62M | -9.00M | -9.56M |
| Financing Cash Flow | 21.56M | 16.79M | 537.00K | 26.00K | 47.13M |
Corline Biomedical AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:CLBIO
Corline Biomedical AB
16.45
7.81
90.39%
DE:5IU
Isofol Medical AB
0.04
-0.08
-65.35%
DE:1XT
Xintela AB
0.01
>-0.01
-40.91%
DE:8E8
Elicera Therapeutics AB
0.49
0.25
107.17%
DE:2E9
Intervacc AB
0.02
>-0.01
-20.69%
DE:BTPC
Active Biotech AB
0.01
<0.01
20.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.